Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 51: Pharmacokinetics and Pharmacodynamics

Pharmacokinetics of 9-nitrocamptothecin (9NC) and 9- aminocamptothecin (9AC) in SCID mice bearing human colon xenografts, HT29

Julie L. Eiseman, Robert A. Parise, Erin Joseph, Sandra Strychor, Robert S. Parker, Merrill J. Egorin and William C. Zamboni
Julie L. Eiseman
University of Pittsburgh Cancer Institute and Departments of Medicine, Pharmacology, and Pharmaceutical Sciences, Pittsburgh, PA and University of Pittsburgh School of Engineering, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Parise
University of Pittsburgh Cancer Institute and Departments of Medicine, Pharmacology, and Pharmaceutical Sciences, Pittsburgh, PA and University of Pittsburgh School of Engineering, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin Joseph
University of Pittsburgh Cancer Institute and Departments of Medicine, Pharmacology, and Pharmaceutical Sciences, Pittsburgh, PA and University of Pittsburgh School of Engineering, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Strychor
University of Pittsburgh Cancer Institute and Departments of Medicine, Pharmacology, and Pharmaceutical Sciences, Pittsburgh, PA and University of Pittsburgh School of Engineering, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert S. Parker
University of Pittsburgh Cancer Institute and Departments of Medicine, Pharmacology, and Pharmaceutical Sciences, Pittsburgh, PA and University of Pittsburgh School of Engineering, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merrill J. Egorin
University of Pittsburgh Cancer Institute and Departments of Medicine, Pharmacology, and Pharmaceutical Sciences, Pittsburgh, PA and University of Pittsburgh School of Engineering, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William C. Zamboni
University of Pittsburgh Cancer Institute and Departments of Medicine, Pharmacology, and Pharmaceutical Sciences, Pittsburgh, PA and University of Pittsburgh School of Engineering, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2004
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 45, 2004

Abstract

5401

Introduction: 9NC is an orally administered camptothecin analogue that has completed Phase III trials in pancreatic cancer. However, limited data are available regarding tissue distribution of 9NC and its active metabolite, 9AC. We developed a sensitive and specific LC-MS/MS assay for quantitating 9NC and 9AC and used it to define the plasma and tumor pharmacokinetics of 9NC and 9AC in female SCID mice bearing HT29 human colon xenografts. Methods: 9NC was administered po at 0.44 or 1.0 mg/kg. Groups of 3 mice were euthanized at 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 420, and 1440 min after administration of 9NC or 5 min after administration of vehicle. Blood and tissues were collected, and blood was immediately centrifuged to obtain plasma. Tissues were weighed, snap frozen, and stored at -70 o C. 9NC and 9AC in plasma and tumor were converted to their respective lactone forms, and the concentrations of each were determined by LC-MS/MS. The LC-MS/MS assay used: camptothecin as an internal standard; either methanol (plasma) or acetonitrile (tissues) protein precipitation; a Phenomenex Luna C(18)2 (4.5 μm, 150 ×2 mm) analytical column; an isocratic mobile phase of 0.1% formic acid in acetonitrile:50 μM ammonium acetate buffer, pH 5.0 (40:60, v/v); and electropositive spray mode electron ionization with MRM detection. Concentration-versus-time data were modeled with non-compartmental methods utilizing the Lagrange function. Results: The retention times of 9AC, internal standard, and 9NC were 2.8, 4.6, and 7.9 min, respectively. The assay had a run time of 10 min, a lower limit of quantitation of 1.0 ng/ml, and was linear between 1 and 1000 ng/ml. Peak plasma 9NC and 9AC concentrations and areas under the concentration vs. time curve (AUC’s) were proportional to dose. After 0.44 and 1 mg/kg 9NC, peak plasma concentrations of 9NC were 34 and 90 ng/ml and occurred at 5 and 15 minutes, respectively. Plasma 9NC AUC was 1726 ng/ml/min at 0.44 mg/kg and 4111 ng/ml/min at 1 mg/kg. 9NC clearance was 255 ml/min/kg at 0.44 mg/kg and 243 ml/min/kg at 1mg/kg. 9NC half-lives were 86 and 35 min for doses of 9NC of 0.44 and 1 mg/kg, respectively. Peak plasma 9AC concentrations were 5 and 11 ng/ml and occurred at 5 and 15 min after 9NC doses of 0.44 and 1 mg/kg, respectively. 9AC AUC was 687 ng/ml/min at 0.44 mg/kg and 1135 ng/ml/min at 1.0 mg/kg. Peak tumor concentrations of 9NC were 5 and 25 ng/ml and occurred at 30 min after doses of 0.44 and 1 mg/kg 9NC. Tumor 9NC AUC’s were 1094 and 2016 ng/ml/min after 9NC doses of 0.44 and 1 mg/kg, respectively. Conclusion: The LC-MS/MS method developed is sensitive and robust and should prove suitable for use in clinical studies of 9NC. The 9NC data suggest that the murine pharmacokinetics are linear with dose and that tumor concentrations of 9NC and 9AC are above the concentrations required for in vitro anti-tumor activity. Support: Whitaker Foundation Grant RG-01-0311 and NCI P30 CA47904.

  • American Association for Cancer Research
Previous
Back to top
April 2004
Volume 64, Issue 7 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacokinetics of 9-nitrocamptothecin (9NC) and 9- aminocamptothecin (9AC) in SCID mice bearing human colon xenografts, HT29
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Pharmacokinetics of 9-nitrocamptothecin (9NC) and 9- aminocamptothecin (9AC) in SCID mice bearing human colon xenografts, HT29
Julie L. Eiseman, Robert A. Parise, Erin Joseph, Sandra Strychor, Robert S. Parker, Merrill J. Egorin and William C. Zamboni
Cancer Res April 1 2004 (64) (7 Supplement) 1246;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pharmacokinetics of 9-nitrocamptothecin (9NC) and 9- aminocamptothecin (9AC) in SCID mice bearing human colon xenografts, HT29
Julie L. Eiseman, Robert A. Parise, Erin Joseph, Sandra Strychor, Robert S. Parker, Merrill J. Egorin and William C. Zamboni
Cancer Res April 1 2004 (64) (7 Supplement) 1246;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Trastuzumab (recombinant humanized monoclonal anti-HER2) clearance is not altered in a non-clinical model of doxorubicin-induced cardiotoxicity
  • Validation of tumor bearing Nude rats as a model to study anticancer drug pharmacokinetic/pharmacodynamic (PK/PD) relationships
  • Development of a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for halofuginone and its application to pharmacokinetic studies in beagle dogs
Show more Experimental and Molecular Therapeutics 51: Pharmacokinetics and Pharmacodynamics
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement